RSI Chief Medical Officer, Dr. Donald R. Mattison, in collaboration with colleagues from the Institute for Safe Medication Practices and Wake Forest University, evaluated and compared the safety profiles of newer contraceptives using 43,324 adverse event case reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), for the two years ending July 2017. The presentation on Saturday, March 10, 2018 in San Diego described the strong safety profiles of the newer contraceptives, as well as issues of concern.
For more details see the presentation poster here.
More RSI News
IAI climate change report
The International Aluminium Institute (IAI) recently commissioned Climate Risk Institute (CRI) and Risk Sciences International (RSI) to produce a series of informational tools evaluating and…
Quinolones and risk of acute liver failure
Quinolones, are a class of widely used and popular powerful antibiotics with broad coverage. RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski,…
RSI launches Global Risk Census
Risk Sciences International has launched The Global Risk Census. The goal of the Census is to provide insights into important risks that need to be…
US FDA FAERS and quinolones
Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised…